Scope of the PIP in the EU: easier accessibility to the paediatric rewards and simplification of administrative requirements
This article was originally published in SRA
Executive Summary
The European Medicines Agency’s policy on changes in the scope of paediatric investigation plan decisions will make it easier for drug companies to reap the available rewards as well as cut down on the paperwork, insist Paolo Tomasi and Agnes Saint Raymond.